Pharmaceutical industry: Getting involved in EMA activities
Submitted by Anonymous (not verified) on 4 September 2026 - 11:00
Pharmaceutical industry: Getting involved in EMA activities
Scientific advice and protocol assistance
Submitted by Anonymous (not verified) on 4 September 2026 - 11:00
Scientific advice and protocol assistance
Human medicines European public assessment report (EPAR): Repatha, evolocumab, Date of authorisation: 17/07/2015, Revision: 28, Status: Authorised
Submitted by Anonymous (not verified) on 4 September 2026 - 10:26
Human medicines European public assessment report (EPAR): Repatha, evolocumab, Date of authorisation: 17/07/2015, Revision: 28, Status: Authorised
New EU supply chain to end Visudyne shortage
Submitted by Anonymous (not verified) on 4 September 2026 - 10:00
New EU supply chain to end Visudyne shortage
Women's health
Submitted by Anonymous (not verified) on 4 September 2026 - 9:15
Women's health
Scientific and technical recommendations: Veterinary Medicines Regulation
Submitted by Anonymous (not verified) on 4 September 2026 - 9:00
Scientific and technical recommendations: Veterinary Medicines Regulation
Human medicines European public assessment report (EPAR): Onureg, azacitidine, Date of authorisation: 17/06/2021, Revision: 5, Status: Authorised
Submitted by Anonymous (not verified) on 3 September 2026 - 15:40
Human medicines European public assessment report (EPAR): Onureg, azacitidine, Date of authorisation: 17/06/2021, Revision: 5, Status: Authorised
Sponsor guidance: New safety module on the annual safety report
Submitted by Anonymous (not verified) on 3 September 2026 - 15:30
Sponsor guidance: New safety module on the annual safety report
Support to SMEs
Submitted by Anonymous (not verified) on 3 September 2026 - 15:23
Support to SMEs
PSUSA/00000414/202601
Submitted by Anonymous (not verified) on 3 September 2026 - 15:05
PSUSA/00000414/202601